Learning Objectives
Upon completion of this activity, participants should be able to:
- Identify agents under investigation in melanoma that target signaling pathways that are dysregulated due to mutations in BRAF
- Discuss the current status of clinical development of these agents
- Describe cell-based immunomodulatory therapy approaches for enhancing immune response to melanoma
- Summarize recent data on their efficacy
- Describe possible approaches for enhancing tumor suppressor gene function in melanoma
- Discuss targeted immunologic agents under study in melanoma and the current status of their clinical development
Topics covered include:
- Introduction
- Targeting Dysfunctional Signaling Pathways
- Looking Beyond the Pathways: Chaperones and Suppressors
- Tipping the Balance Toward Apoptosis
- Immunomodulatory Therapies
- Novel Immunomodulatory Agents Targeting CTLA-4
- Conclusions